AJCN Yamada Bee Farm Grant for Honeybee Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stanko, R. T.
Right arrow Articles by Arch, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanko, R. T.
Right arrow Articles by Arch, J. E.
Agricola
Right arrow Articles by Stanko, R. T.
Right arrow Articles by Arch, J. E.

American Journal of Clinical Nutrition, Vol 56, 950-954, Copyright © 1992 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Plasma lipid concentrations in hyperlipidemic patients consuming a high- fat diet supplemented with pyruvate for 6 wk

RT Stanko, HR Reynolds, KD Lonchar and JE Arch
Clinical Nutrition Unit, Montefiore University Hospital, Pittsburgh, PA 15213.

We evaluated the effects of a three-carbon compound, pyruvate, on plasma lipid concentrations in hyperlipidemic patients consuming a high- cholesterol (560-620 mg), high-fat (45-47% of energy; 18-20% of energy as saturated fatty acid), anabolic diet (0.11-0.12 MJ/kg body wt) for 6 wk. Forty subjects consumed the diet, randomly supplemented with 36-53 g pyruvate (n = 19) or 21-37 g polyglucose (placebo, Polycose, n = 21) as a portion of carbohydrate energy. Plasma cholesterol and LDL- cholesterol concentrations were unchanged in the placebo group, but decreased by 4% and 5%, respectively, in the pyruvate group (P < 0.05 vs placebo). Plasma HDL-cholesterol, HDL3-cholesterol, and triglyceride concentrations were similar in both groups. Resting heart rate, diastolic blood pressure, and rate-pressure product were unchanged after 6 wk of therapy in the placebo group, but decreased by 9%, 6%, and 12%, respectively with pyruvate supplementation (P < 0.05 vs placebo). We conclude that pyruvate supplementation of a high-fat, high- cholesterol, anabolic diet will decrease plasma cholesterol and LDL- cholesterol concentrations without affecting the HDL-cholesterol concentration.


This article has been cited by other articles:


Home page
 JPEN J Parenter Enteral NutrHome page
L. Cicalese
Reviews: Pyruvate in Organ Transplantation
JPEN J Parenter Enteral Nutr, July 1, 2001; 25(4): 216 - 218.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by The American Society for Nutrition